These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 3024197)

  • 1. An observational analysis of the effect of the selective kappa opioid agonist, U-50,488H, on feeding and related behaviours in the rat.
    Jackson A; Cooper SJ
    Psychopharmacology (Berl); 1986; 90(2):217-21. PubMed ID: 3024197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-dimensional analyses of behavior in mice treated with U-50,488H, a purported kappa (non-mu) opioid agonist.
    Ukai M; Kameyama T
    Brain Res; 1985 Jul; 337(2):352-6. PubMed ID: 2992682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioural effect of pretreatment with opioid antagonists and sigma binding site ligands on the abnormal motor response produced by the kappa opioid agonist U50,488H in guinea pigs.
    Brent PJ
    Neuropharmacology; 1993 Aug; 32(8):751-60. PubMed ID: 8413839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Observational analysis of the effects of kappa opioid agonists an open field behaviour in the rat.
    Jackson A; Cooper SJ
    Psychopharmacology (Berl); 1988; 94(2):248-53. PubMed ID: 2895484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioural effects of selective mu-, kappa-, and delta-opioid agonists in neonatal rats.
    Jackson HC; Kitchen I
    Psychopharmacology (Berl); 1989; 97(3):404-9. PubMed ID: 2541460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered neurochemical and behavioral development of 10-day-old rats perinatally exposed to the kappa opioid agonist U-50,488H.
    Shieh GJ; Walters DE
    Neurosci Lett; 1994 Jul; 176(1):37-40. PubMed ID: 7970232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The kappa-opioid U-50,488H suppresses the initiation of nocturnal spontaneous drinking in normally hydrated rats.
    Badiani A; Stewart J
    Psychopharmacology (Berl); 1992; 106(4):463-73. PubMed ID: 1315973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ventral pallidal microinjections of receptor-selective opioid agonists produce differential effects on circling and locomotor activity in rats.
    Hoffman DC; West TE; Wise RA
    Brain Res; 1991 Jun; 550(2):205-12. PubMed ID: 1653084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The stimulation of central kappa opioid receptors decreases male sexual behavior and locomotor activity.
    Leyton M; Stewart J
    Brain Res; 1992 Oct; 594(1):56-74. PubMed ID: 1334765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a selective kappa-opioid agonist, U-50,488H, on morphine dependence in rats.
    Fukagawa Y; Katz JL; Suzuki T
    Eur J Pharmacol; 1989 Oct; 170(1-2):47-51. PubMed ID: 2558895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of chronic administration of U-50,488H, a kappa-opioid receptor agonist, on central dopamine D2 receptors of the rat.
    Veeranna ; Reddy PL; Bhargava HN
    Eur J Pharmacol; 1993 Apr; 235(1):23-30. PubMed ID: 8390939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The site of anti-arthritic action of the kappa-opioid, U-50, 488H, in adjuvant arthritis: importance of local administration.
    Wilson JL; Nayanar V; Walker JS
    Br J Pharmacol; 1996 Aug; 118(7):1754-60. PubMed ID: 8842441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A selective kappa-opioid agonist, U-50,488H, blocks the development of tolerance to morphine analgesia in rats.
    Yamamoto T; Ohno M; Ueki S
    Eur J Pharmacol; 1988 Oct; 156(1):173-6. PubMed ID: 2850208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The selective kappa-opioid agonist, U-50,488H, produces antinociception in the rat via a supraspinal action.
    Czlonkowski A; Millan MJ; Herz A
    Eur J Pharmacol; 1987 Oct; 142(1):183-4. PubMed ID: 2826175
    [No Abstract]   [Full Text] [Related]  

  • 15. Ventral tegmental injections of morphine but not U-50,488H enhance feeding in food-deprived rats.
    Noel MB; Wise RA
    Brain Res; 1993 Dec; 632(1-2):68-73. PubMed ID: 8149246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A kappa opiate agonist, U50,488H, enhances energy expenditure in rats.
    Mandenoff A; Seyrig JA; Betoulle D; Brigant L; Melchior JC; Apfelbaum M
    Pharmacol Biochem Behav; 1991 May; 39(1):215-7. PubMed ID: 1656474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the kappa-receptor agonist, U-50,488H, on cerebral ischemia-induced impairment of working memory assessed in rats by a three-panel runway task.
    Ohno M; Yamamoto T; Ueki S
    Eur J Pharmacol; 1991 Feb; 193(3):357-61. PubMed ID: 1647321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction between the cardiovascular effects of clonidine and the kappa-opioid agonist U-50,488H in the anterior hypothalamic area of the rat brain.
    Verberne AJ; Louis WJ
    J Pharm Pharmacol; 1989 Feb; 41(2):131-3. PubMed ID: 2568424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of morphine in rats treated chronically with U-50,488 H, a kappa opioid receptor agonist.
    Bhargava HN; Ramarao P; Gulati A
    Eur J Pharmacol; 1989 Mar; 162(2):257-64. PubMed ID: 2542058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nor-binaltorphimine decreases deprivation and opioid-induced feeding.
    Levine AS; Grace M; Billington CJ; Portoghese PS
    Brain Res; 1990 Nov; 534(1-2):60-4. PubMed ID: 1963567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.